Filter your results
- 2
- 1
- 3
- 3
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 1
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19Therapeutic Drug Monitoring, 2022, ⟨10.1097/FTD.0000000000001014⟩
Journal articles
hal-03776369v1
|
||
|
Pharmacologic treatment of transplant recipients infected with SARS-CoV-2 considerations regarding therapeutic drug monitoring and drug-drug interactionsTherapeutic Drug Monitoring, 2020, 42 (3), pp.360-368. ⟨10.1097/FTD.0000000000000761⟩
Journal articles
hal-02563361v1
|
||
|
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyTherapeutic Drug Monitoring, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Journal articles
hal-03216543v1
|